The Oxford AI in Drug Discovery and Medicine Programme targets professionals aiming to integrate machine learning into their workflows without requiring prior coding experience. Participants will examine how AI can refine target identification, biomarker discovery, and patient stratification, utilizing industry-standard tools like MedChemica and Target Safety. Beyond technical implementation, the curriculum addresses critical challenges such as algorithmic bias, model explainability, and the responsible deployment of technology in sensitive healthcare environments.

This initiative marks the Nuffield Department of Medicine’s entry into 2U’s expansive digital education portfolio, which already includes partnerships with Oxford’s Saïd Business School and the Faculty of Law. Dr. Abigail Rickard, head of academic programs at the department, noted that the course aims to equip researchers to translate emerging technologies into tangible medical advances. The collaboration is set to deepen later this year with the planned launch of the Oxford Nuffield Healthcare Management Programme, signaling a broader effort to align Oxford’s research leadership with the evolving demands of the global life sciences workforce.